In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

Following the federal government's changes to COVID-19 vaccine eligibility and recommendations in 2025, many people are ...

By reducing inflammation, the researchers were able to prevent both the buildup of immune cells and the formation of these ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The Indianapolis drug giant's stock (LLY) reached an intraday high of $1,061.17 in morning trading Friday, which was above the threshold of $1,057.78 needed for Lilly to become the 10th U.S. company ...

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.